MDP-Lys (L18), a synthetic muramyl dipeptide derivative, enhances antitumor activity of an inactivated tumor vaccine

Journal of Microbiology and Biotechnology

Volumn 10, Issue 3, 2000, Pages 399-404

  Yoo, Yung Choon ^a   Park, Seung Yong ^b   Lee, Kyung Bok ^a   Azuma, Ichiro ^c,d  

^a Konyang University   (South Korea)

^b Konkuk University   (South Korea)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HAKODATE NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

Author keywords

Adjuvant; Bacteria cell wall; MDP; Tumor metastasis; Tumor vaccine

Indexed keywords

MURAMYL DIPEPTIDE DERIVATIVE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; DRUG EFFECT; IMMUNOMODULATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN;

EID: 12944277166     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Adam, A., R. Ciorbaru, F. Ellouz, J.-F. Petit, and E. Lederer. 1974. Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem. Biophys. Res. Commun. 56: 561-567.
2. Adam, A., M. Devys, V. Souvannavong, P. Lefrancier, J. Choay, and E. Lederer. 1976. Correlation of structure and adjuvant activity of N-acetylmuramyl-L-ananyl-D-isoglutamine (MDP), its derivatives and analogs. Antiadjuvant and competition properties of stereo-isomers. Biochem. Biophys. Res. Commun. 72: 336-356.
3. Akasaki, M. 1988. Activation of immune responses by muroctasin. Arzneim.- Forsch./Drug Res. 38(II): 976-977.
4. Azuma, I., K. Kamisango, I. Saiki, Y. Tanio, S. Kobayashi, and Y. Yamamura. 1980. Adjuvant activity of N-acetyl muramyl dipeptides for the induction of delayed-type hypersensitivity to azobenzene-arsonate-N-acetyl-L-tyrosine in guinea pig. Infect. Immun. 29: 1193-1196.
5. Azuma, I. 1992. Synthetic immunoadjuvants: Application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 10: 1000-1006.
6. Chedid, L., L. Carelli, and F. Audibert. 1979. Recent development concerning muramyldipeptide, a synthetic immunoregulating molecule. J. Reticuloendothel. 26: 631-641.
7. Durette, P. L., C. P. Jr. Dorn, A. Friedman, and A. Schlabach. 1982. Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl derivatives of N-acetylmuramyl dipeptide. J. Med. Chem. 25: 1028-1033.
8. Ellouz, F., A. Adam, R. Ciorbaru, and E. Lederer. 1974. Minimal structure requirement for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59: 1317-1325.
9. Fidler, I. J. and A. J. Schroit. 1984. Synergism between lymphokine and muramyl dipeptide encapsulated in liposome: In situ activation of macrophage and therapy of spontaneous cancer metastasis. J. Immunol. 133: 515-518.
10. Furuse, K. and A. Sakuma. 1989. Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia. Arzneim.-Forsch./Drug Res. 39: 915-917.
11. Han, M. J., H. Y. Park, and D. H. Kim. 1999. Protective effects of Bifidobacterium spp. on experimental colon carcinogenesis with 1,2-dimethylhydrazine. J. Microbiol. Biotechnol. 9: 368-370.
12. Galelli, A., P. Lefrancier, and L. Chedid. 1984. Colony-stimulating activity induced by synthetic muramyl peptides: Variation with chemical structure and association with anti-infectious activity. Infect. Immun. 46: 495-500.
13. Iida, J., I. Saiki, C. Ishihara, and T. Azuma. 1989. Prophylactic activity against Sendai virus infection and macrophage activation with lipophilic derivatives of N-acetylglucosaminyl-muramyl tri- or tetrapeptides. Vaccine 7: 225-228.
14. e-stearoyl-L-lysine in mice. Vaccine 5: 295-301.
15. e-stearoyl-L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice. Vaccine 7: 309-313.
16. Ishihara, C., M. Miyazawa, J. Nishio, I. Azuma, and B. Chesebro. 1992. Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukemia retrovirus-induced disease. Vaccine 10: 353-356.
17. Kaji, M., Y. Kaji, M. Kaji, T. Honda, and T. Oka, et al. 1992. Phase I clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine 10: 663-667.
18. Kang, T. Y., S. H. Park, and T. B. Choe. 1994. Immunostimulating effects of cell wall components isolated from Lactobacillus plantarum. J. Microbiol. Biotechnol. 4: 195-199.
19. Koff, W. C., I. J. Fiedler, S. D. Showalter, M. K. Chakrabarty, B. Hampar, L. M. Ceccorulli, and E. S. Kleinerman. 1984. Human monocytes activated by immunomodulators in liposome lyse herpes virus infected but not normal cells. Science 24: 1007-1009.
20. Lovett, D., B. Kozan, M. Resch, and D. Gemsa. 1986. Macrophage cytotoxicity: Interleukin 1 as a mediator of tumor cytostasis. J. Immunol. 136: 350-357.
21. Matsumoto, K., H. Ogawa, O. Nagase, T. Kusama, and I. Azuma. 1981. Stimulation of nonspecific resistance to infection induced by muramyl dipeptides. Microbial Immunol. 25: 1047-1058.
22. Matsumoto, K., H. Ogawa, T. Kusama, O. Nagase, N. Sawaki, M. Inage, S. Kusumoto, T. Shiba, and I. Azuma. 1981. Stimulation of nonspecific resistance induced by 6-O-acyl muramyl dipeptide analogs in mice. Infect. Immun. 32: 748-758.
23. e-stearoyllysine. Infect. Immun. 39: 1029-1215.
24. Otani, T., T. Une, and Y. Osada. 1988. Stimulation of non-specific resistance to infection by muroctasin. Arzneim.-Forsch./Drug Res. 38(II): 969-976.
25. Platzer, E., S. Oez, K. Weite, A. Sendler, J. L. Gabrilove, R. Mertelsmann, M. A. Moore, and J. R. Kalden. 1986. Human pluripotent hemopoietic colony stimulating factor: Activities on human and marine cell. Immunobiology 172: 185-193.
26. Saiki, I., S. Saito, C. Fujita, H. Ishida, J. Iida, J. Murata, A. Hasegawa, and I. Azuma. 1988. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogs. Vaccine 6: 238-244.
27. Svedersky, L. P., C. V. Benton, W. H. Berger, E. Rinderknecht, R. H. Harkins, and M. A. Palladino. 1984. Biological and antigenic similarities of murine interferon-γ and macrophage-activating factor. J. Exp. Med. 159: 812-827.
28. Tamura, M., Y. C. Yoo, K. Yoshimatsu, R. Yoshida, T. Oka, K. Ohkuma, J. Arikawa, and I. Azuma. 1995. Effect of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine 13: 77-82.
29. Tsubura, E., T. Nomura, H. Niitani, T. Osamura, M. Tanaka, and K. Ota, et al. 1988. Restorative activity of muroctasin on leukopenia associated with anticancer treatment. Arzneim.-Forsch./Drug Res. 38: 1070-1074.
30. Tsujimoto, M., S. Kotani, T. Shiba, and S. Kusumoto. 1986. Adjuvant activity of 6-O-acyl-muramyl dipeptides to enhance primary cellular and humoral immune responses in guinea pigs: Dose response and local reactions observed with selected compounds. Infect. Immun. 53: 517-521.
31. Yamaguchi, F., M. Akasaki, and W. Tsukada. 1988. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin. Arzneim.-Forsch./Drug Res. 38: 980-983.
32. Yamaguchi, F., K. Akahane, T. Takashi, and W. Tsukada. 1988. Production of colony-stimulating factor from macrophages by muroctasin. Arzneim.-Forsch./Drug Res. 38: 983-986.
33. Yoo, Y. C., I. Saiki, K. Sato, and I. Azuma. 1992. B30-MDP, a synthetic derivative for tumour vaccination to enhance antitumour immunity and ancimetastatic effect in mice. Vaccine 10: 792-797.
34. Yoo, Y. C., I. Saiki, K. Sato, and I. Azuma. 1994. MDP-Lys (L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumors in mice. Vaccine 12: 175-180.
35. Yoo, Y. C., K. Yoshimatsu, R. Hatsuse, M. Tamura, R. Yoshida, S. Tono-oka, J. Arikawa, and I. Azuma. 1995. Effect of MDP-Lys (L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice. Vaccine 13: 1300-1305.
36. Yoo, Y. C., S. Watanabe, R. Watanabe, K. Hata, K. Shimazaki, and I. Azuma. 1997. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res. 88: 184-190.
37. Yoo, Y. C., K. Yoshimatsu, Y. Koike, R. Hatsuse, K. Yamanishi, O. Tanishita, J. Arikawa, and I. Azuma. 1998. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine. Vaccine 2/3: 216-224.